Incyte (INCY) PT Lowered to $86 at Morgan Stanley
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
- Equities end higher as Anthropic's IPO filing buoys AI stocks
- Anthropic files for Nasdaq IPO as revenue jumps to $16.3 billion
- Meta reverses losses to rise as investors weigh $35 billion AI funding plan
- Post-election relief ahead for markets, says Morgan Stanley
- Musk says SpaceX raised $40 billion in debt, warns of neocloud collapse
Tweet
Share
E-mailGet Alerts INCY Hot Sheet
Price: $113.31 -2.07%
Rating Summary:
18 Buy, 17 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 3 | Down: 4 | New: 1
Rating Summary:
18 Buy, 17 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 3 | Down: 4 | New: 1
Join SI Premium – FREE
Morgan Stanley analyst Vikram Purohit lowered the price target on Incyte (NASDAQ: INCY) to $86.00 (from $93.00) while maintaining a Equalweight rating.
You May Also Be Interested In
- Incyte cancer drug data shown at ESMO 2026 congress
- Whitehaven Coal Ltd. (WHC:AU) (WHITF) PT Raised to AUD8.05 at UBS
- NOBA Bank Group (NOBA:SS) PT Lowered to SEK86 at Citi
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
